Herd Immunity Conferred By Hepatitis B Vaccination Increases the Protection Efficacy against Hepatitis B Virus Infection

Crossmark: check for updates

Authors

  • Yuting Wang Department of Immunology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China; State Key Lab of Molecular Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
  • Ling-Ling Lu Qidong People's Hospital and Qidong Liver Cancer Institute, Qidong, Jiangsu Province 226200, China
  • Dongmei Wang Department of Immunology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China; State Key Lab of Molecular Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
  • Chunfeng Qu Department of Immunology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China; State Key Lab of Molecular Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

DOI:

https://doi.org/10.17140/VROJ-1-103

Keywords:

Hepatitis B virus, Hepatitis B virus infection, Primary liver cancer, Vaccine protection

Abstract

Most of the chronic infections with Hepatitis B Virus (HBV) are acquired in perinatal period or in early life in China. We conducted HBV serosurveys in the same community among the age 5-6 year old children who were born in 1979-1980, in 1985-1986, and in 2002-2003, respectively. The seropositive rate of HBV surface antigen (HBsAg) was 11.43% in the unvaccinated population. It decreased to 2.08% among the vaccinated children born in the same year. With increased vaccination coverage the HBsAg seropositive rate decreased to 0.24% among the age 6-7 year old children born in 2002-2003, with 98.21% protection efficacy. Herd immunity conferred by HBV vaccination increases the protection efficacy against HBV infection.

References

Chen J, Peto R, Pan WH, Liu BQ, Campbell TC. Mortality, biochenmistry, diet and lifestyle in rural China. Oxford, Britain; Oxford University Press 2006.

McMahon BJ. The natural history of chronic hepatitis B vi-rus infection. Hepatology. 2009; 49(5 Suppl): S45-S55. doi: 10.1002/hep.22898

Xia GL, Liu CB, Cao HL, Bi SL, Zhan MY, Su CA, et al. Prevalence of hepatitis B and C virus infections in the general Chinese population: results from a nationwide cross-sectional seroepidemiologic study of hepatitis A, B,C, D and E virus in-fections in China, 1992. Int Hepatol Commun. 1996; 5(1): 62- 73. doi: 10.1016/S0928-4346(96)82012-3

Zuckerman AJ, Sun TT, Linsell A, Stjernsward J. Prevention of Primary Liver Cancer-Report on a Meeting of a W.H.O. Sci-entific Group. Lancet. 1983; 1(8322): 463-465. doi: 10.1016/ S0140-6736(83)91454-X

Sun Z, Ming L, Zhu X, Lu J. Prevention and control of hepati-tis B in China. J Med Virol. 2002; 67(3): 447-450. doi: 10.1002/ jmv.10094

Chang MH. Hepatitis B virus infection. Semin Fetal Neonatal Med. 2007; 12(3): 160-167. doi: 10.1016/j.siny.2007.01.013

Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, Zhang Y, et al. Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination. Vaccine. 2009; 27(47): 6550-6557. doi: 10.1016/j.vaccine.2009.08.048

Chinese Society of Hepatology, Chinese Medical Association. Guidelines for prevention of chronic hepatitis-Chronic Hepatitis B. 2015. Vaccin Res Open J

Downloads

Published

2016-04-18

How to Cite

Yuting Wang, Ling-Ling Lu, Dongmei Wang, & Chunfeng Qu. (2016). Herd Immunity Conferred By Hepatitis B Vaccination Increases the Protection Efficacy against Hepatitis B Virus Infection. Vaccination Research, 1(1), 10–12. https://doi.org/10.17140/VROJ-1-103

Issue

Vol. 1 No. 1 (2016): Volume 1 Issue 1 2016

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All content published in Vaccination Research (VR) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.